-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Lumexa Imaging Hldgs, Raises Price Target to $17

Benzinga·11/17/2026 14:40:15
Listen to the news
Barclays analyst Andrew Mok maintains Lumexa Imaging Hldgs (NASDAQ:LMRI) with a Overweight and raises the price target from $13 to $17.